How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Infusion Services Market
- By Service Type: Intravenous (IV) Infusion Therapy, Subcutaneous Infusion Therapy, Intramuscular Infusion Therapy, Epidural Infusion Therapy, Intra-arterial Infusion Therapy
- By Therapeutic Area: Oncology Infusion Services, Immunotherapy Infusion Services, Antibiotic Infusion Services, Pain Management Infusion Services, Hydration Therapy, Nutritional Infusion Therapy
- By End User: Hospital-Based Infusion Centers, Home Healthcare Infusion Services, Specialty Clinics, Ambulatory Infusion Centers, Long-Term Care Facilities
- By Drug Class: Monoclonal Antibodies, Chemotherapy Agents, Biologics, Antibiotics, Electrolyte and Hydration Solutions
- By Administration Setting: Inpatient Infusion Services, Outpatient Infusion Services, Home Infusion Services
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Intravenous (IV) Infusion Therapy leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 308 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Infusion Services Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
Therapeutic Area 6
End User 5
Drug Class 5
Administration Setting 3
Companies profiled
Baxter International Inc.
B. Braun Melsungen AG
Fresenius Kabi AG
Hospira (a Pfizer company)
ICU Medical Inc.
Terumo Corporation
Smiths Medical (a division of ICU Medical)
Nipro Corporation
Becton
Dickinson and Company (BD)
Grifols
S.A.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Fresenius Kabi AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Hospira (a Pfizer company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ICU Medical Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Smiths Medical (a division of ICU Medical)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Nipro Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Grifols
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sagent Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Mylan N.V. (now part of Viatris)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Pfizer Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →AbbVie Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Sandoz (a Novartis division)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,327M by 2033 · 11.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Intravenous (IV) Infusion Therapy47.2
- Subcutaneous Infusion Therapy10.5
- Intramuscular Infusion Therapy12.3
- Epidural Infusion Therapy9.7
- Intra-arterial Infusion Therapy20.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$726.7M → $1,866M · 12.5%
Europe$506.5M → $1,271M · 12.2%
Asia Pacific$462.4M → $1,077M · 11.1%
Latin America$286.3M → $742.7M · 12.7%
Middle East and Africa$220.2M → $485.7M · 10.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.632026
11.632027
11.642028
11.662029
11.682030
11.682031
11.712032
11.712033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Baxter International Inc.20.3
- B. Braun Melsungen AG22.0
- Fresenius Kabi AG3.7
- Hospira (a Pfizer company)8.9
- ICU Medical Inc.6.8
- Terumo Corporation10.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type12.6%
Therapeutic Area27.8%
End User24.0%
Drug Class24.7%
Administration Setting10.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.3
- Europe23.4
- Asia Pacific19.8
- Latin America13.6
- Middle East and Africa8.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Baxter International Inc. | 83 | 97 | 87 | 76 | 85 | 97 | 88 |
| B. Braun Melsungen AG | 85 | 82 | 91 | 83 | 92 | 76 | 85 |
| Fresenius Kabi AG | 70 | 76 | 64 | 78 | 74 | 75 | 73 |
| Hospira (a Pfizer company) | 61 | 61 | 62 | 76 | 62 | 71 | 66 |
| ICU Medical Inc. | 73 | 57 | 53 | 73 | 66 | 55 | 63 |
| Terumo Corporation | 66 | 55 | 53 | 66 | 69 | 58 | 61 |
| Smiths Medical (a division of ICU Medical) | 55 | 52 | 48 | 43 | 62 | 61 | 54 |
| Nipro Corporation | 47 | 56 | 39 | 40 | 54 | 56 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Baxter International Inc.
- B. Braun Melsungen AG
- Fresenius Kabi AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Baxter International Inc. | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| B. Braun Melsungen AG | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Fresenius Kabi AG | − | ◐ | − | ◐ | ◐ | ◐ |
| Hospira (a Pfizer company) | ◐ | ✓ | ◐ | ◐ | − | ✓ |
| ICU Medical Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Terumo Corporation | ◐ | − | − | ✓ | ◐ | ◐ |
| Smiths Medical (a division of ICU Medical) | ◐ | − | − | ◐ | ◐ | ◐ |
| Nipro Corporation | − | ◐ | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Baxter International Inc.88
2B. Braun Melsungen AG85
3Fresenius Kabi AG73
4Hospira (a Pfizer company)66
5ICU Medical Inc.63
6Terumo Corporation61
7Smiths Medical (a division of ICU Medical)54
8Nipro Corporation49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Baxter International Inc.B. Braun Melsungen AG
Challenger1
Strong scale, closing on the leaders.
Fresenius Kabi AG
Contender3
Focused players with pockets of strength.
Hospira (a Pfizer company)ICU Medical Inc.Terumo Corporation
Niche2
Specialists in a single segment or region.
Smiths Medical (a division of ICU Medical)Nipro Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Infusion Services Market — a $251M beachhead inside a $5.10B market.
Beachhead (SOM)$251Mobtainable near-term
Serviceable (SAM)$1.77Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Intravenous (IV) Infusion Therapy
Best fit — highest urgency & budget in Service Type.
Economic buyer79 fit
Subcutaneous Infusion Therapy
Strong fit — clear ROI and a fast path to value.
End user67 fit
Intramuscular Infusion Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Area & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel29%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Infusion Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified23%
Evaluation15%
Closed-won5%
$20.0KCAC
$72KLTV
3.6:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Infusion Services Market is a durable-growth opportunity — $9.85B by 2033, compounding at 8.0%.
TAM · 2025$5.33Btoday
TAM · 2033$9.85Bforecast
CAGR8.0%2027–2033
Cumulative$66.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.85BTotal addressable market
SAM$3.68BServiceable available market
SOM$745MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.0% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.85BLarge & growingTAM by 2033 at 8.0% CAGR
$3.68BServiceable nowreachable with today’s model
$745MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.68BBear5.2% CAGR
$9.85BBase8.0% CAGR
$12.6BBull10.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Area optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Infusion Services Market — a $4.87B market by 2033. Plan: grow share from 7.5% to 12.6%.
Market size · 2033$4.87Btotal addressable
Market CAGR4.3%2027–2033
Target share12.6%from 7.5% today
Revenue ambition$614Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.5% | 12.6% | On track |
| Revenue | $363M | $614M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 30.2% | 40.0% | At risk |
| Customer retention | 87.9% | 94.5% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Area capability
A defensible second engine — invest in Therapeutic Area to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Area
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $63M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Area
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Infusion Services Market conversation — a $4.74B market you can size, segment and defend in minutes.
Market size · 2033$4.74Btotal opportunity
Growth10.2%CAGR to 2033
Addressable buyers1,473+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 4 mopayback period
$96K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Baxter International Inc.B. Braun Melsungen AGFresenius Kabi AGHospira (a Pfizer company)ICU Medical Inc.Terumo CorporationSmiths Medical (a division of ICU Medical)Nipro Corporation+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Infusion Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Infusion Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Anti-Infective Endotracheal Tube Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportInfusion Pump Testers Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportInfusion Pump Stand Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportAntimicrobial Endotracheal Tube Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportInfusion Pumps & Accessories Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportInfusion Pump Rental Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportArgon Knife Market
Market size, share, segmentation and regional forecast.
$995M market · 2025 base year
View reportInfusion Pump Lithium Battery Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportInfusion Pump and Syringe Pump Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportArthritic Therapeutic Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportInfusion Pump Analyzer Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportArthroscopic Implants Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.